Silver Nanoparticles Irrigant

PreclinicalSmall molecule

Silver Nanoparticles Irrigant is one of 32 small molecule programs targeting Diabetic Foot. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetic FootActive, not recruiting

Diabetic FootPreclinical

Active, not recruiting

Competition

Competitive Landscape

210 competitors in Diabetic Foot

#DrugCompanyPhaseTrials

Isordil

AstraZeneca

Phase 3

1 2

Zyvox

Pfizer

Phase 3

1 3

Cysteine Hydrochloride

Novartis

Phase 3

1 4

Cubicin

BBaxter Healthcare Corporation

Phase 3

1 5

Invanz

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

1 6

Tygacil

PPrism Pharmaceuticals

Phase 3

1 7

Urokinase

Mmedac GmbH

Phase 3

3 8

Bemiparin

RRovi Pharmaceuticals Laboratories

Phase 3

1 9

Biochaperone Combo

AAdocia

Phase 3

1 10

Chitosan

UUniversity Hospital, Basel, Switzerland

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Post Operative Pain1 trial

Evaluation of Antimicrobial Efficacy and Postoperative Pain After Using Silver Nanoparticles and Chitosan Nanoparticles Against Enterococcus Faecalis and Candida Albicans Biofilm

Completed·MMinia University·N/A·NCT06172023·78 enrolled

Diabetic Foot1 trial

Comparative Study of Negative-Pressure Wound Therapy Integrated With Silver Nanoparticle Spray Versus Negative-Pressure Wound Therapy in Post-Revascularization Diabetic Foot Wound Management

Enrolling by invitation·KKafrelsheikh University··NCT07147790·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Silver Nanoparticles Irrigant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Silver Nanoparticles Irrigant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Silver Nanoparticles Irrigant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Minia University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMinia University

Silver Nanoparticles Irrigant

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Post Operative Pain1 trial

Diabetic Foot1 trial

References

Drug Info

Quick Facts

Related News